Cancer vaccines: past, present and future; a review article

Author:

Grimmett Eddie,Al-Share Bayan,Alkassab Mohamad Basem,Zhou Ryan Weng,Desai Advait,Rahim Mir Munir A.,Woldie Indryas

Abstract

AbstractImmunotherapy and vaccines have revolutionized disease treatment and prevention. Vaccines against infectious diseases have been in use for several decades. In contrast, only few cancer vaccines have been approved for human use. These include preventative vaccines against infectious agents associated with cancers, and therapeutic vaccines used as immunotherapy agents to treat cancers. Challenges in developing cancer vaccines include heterogeneity within and between cancer types, screening and identification of appropriate tumour-specific antigens, and the choice of vaccine delivery platforms. Recent advances in all of these areas and the lessons learnt from COVID-19 vaccines have significantly boosted interest in cancer vaccines. Further advances in these areas are expected to facilitate development of effective novel cancer vaccines. In this review, we aim to discuss the past, the present, and the future of cancer vaccines.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism

Reference125 articles.

1. Innate Immunity—Immune Disorders—Merck Manuals Consumer Version [Internet]. [cited 2021 Dec 18]. https://www.merckmanuals.com/en-ca/home/immune-disorders/biology-of-the-immune-system/innate-immunity

2. Acquired Immunity—Immune Disorders—Merck Manuals Consumer Version [Internet]. [cited 2021 Dec 18]. https://www.merckmanuals.com/home/immune-disorders/biology-of-the-immune-system/acquired-immunity

3. Stögerer T, Stäger S. Innate immune sensing by cells of the adaptive immune system. Front Immunol. 2020;11:1081.

4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52.

5. Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2014;21(1):81–5. https://www.nature.com/articles/nm.3773

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3